Vanguard Asset Management’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
KCM
Vanguard Asset Management's BEAM Position: Q3 2026 in Review
Vanguard Asset Management reduced its Beam Therapeutics (BEAM) stake by 3.6% in Q3 2026, selling an estimated $91.3K and leaving 87,077 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #1525.
Vanguard Asset Management first reported a position in BEAM in Q1 2026 and has held it in 3 quarters since. The position peaked at $3.1M in Q2 2026. 264 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.
- Vanguard Asset Management held 87,077 shares of Beam Therapeutics worth $2.13M as of Q3 2026.
- Vanguard Asset Management sold 3,281 Beam Therapeutics shares in Q3 2026, an estimated $91.3K.
- Beam Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1525 holding.
- Vanguard Asset Management first reported a position in Beam Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Asset Management's Beam Therapeutics position peaked at $3.1M in Q2 2026.
- 264 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.
Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.